FaridBouladMD

Pediatric Hematology & Oncology • New York, NY

Vice Chair, Clinical Operations, MSK Kids at MSKCC Medical Director, Pediatric Ambulatory Care Center, MSK Kids at MSKCC Professor, Clinical Pediatrics, Weill Cornell Medical College

Join to view full profile

Dr. Boulad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boulad's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10065
Phone+1 212-639-6684

Fax+1 212-717-3555

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1986 - 1989
New York Medical College (Metropolitan)Residency, Pediatrics, 1983 - 1986
Universite Libre de Bruxelles Faculty of MedicineClass of 1982

Certifications & Licensure

NY State Medical License 1990 - 2025
PA State Medical License 1985 - 1990
American Board of Pediatrics Pediatrics

Clinical Trials

Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission Start of enrollment: 1993 May 01
Completed
Phase 3
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease Start of enrollment: 2006 Nov 20
Completed
Phase 1, Phase 2
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma Start of enrollment: 2007 Nov 13
Completed
Phase 2
Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis Start of enrollment: 1994 Jan 01
Completed
Phase 2
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor Start of enrollment: 2001 May 01
Completed
Phase 2
Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine Start of enrollment: 2001 Jun 01
Completed
Not Applicable
Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major Start of enrollment: 2008 Apr 01
Completed
Not Applicable
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine Start of enrollment: 2009 Sep 25
Completed
Phase 2
ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene Start of enrollment: 2012 Jul 01
Active, not recruiting
Phase 1
Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995 Start of enrollment: 2014 Jun 01
Enrolling by invitation
Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease Start of enrollment: 2014 Sep 01
Active, not recruiting
Phase 1
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia Start of enrollment: 2018 May 15
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

7 citations
Posttransplant Lymphoproliferative Disorder Complicating Hematopoietic Stem Cell Transplantation in a Patient With Dyskeratosis Congenita
Olga L. Bohn, Joseph A. Whitten, Barbara Spitzer, Rachel Kobos, Susan E. Prockop
International Journal of Surgical Pathology. 2013-10-01
157 citations
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J Curran, Steven P. Margossian, Nancy A. Kernan, Lewis B. Silverman, David A. Williams
Blood. 2019-12-26
937 citations
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.
Johannes F. Scheid, Hugo Mouquet, Beatrix Ueberheide, Ron Diskin, Florian Klein
Science. 2011-09-16

Journal Articles

Important Concerns over SARS-CoV-2 Infection in Children with Cancer—Reply
Andrew L Kung, Farid Boulad, JAMA Oncology
COVID-19 in Children with Cancer in New York City
Farid Boulad, Mini Kamboj, Andrew L Kung, JAMA Oncology

Abstracts/Posters

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL
Farid Boulad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019